ticlevaccine.Biopharm.Int23Suppl10,26–34(2010).
46. Fernandes,F.etal.Insectcellsasaproductionplatformofcomplexvirus-like
particles. Expert Rev. Vaccines 12,225–236(2013).
47. Influenza vaccine strategies for broad global access. Available at https://path.
azureedge.net/media/documents/VAC_infl_publ_rpt_10-07.pdf. Accessed August
2021.
48. European Medicines Agency. Assessment report. Supemtek. Procedure No.
EMEA/H/C/005159/0000. Available at https://www.ema.europa.eu/en/documents/
assessment-report/supemtek-epar-public-assessment-report_en.pdf. Accessed 17
February2021.
49. Health Canada. Registerof Innovative Drugs[Updated 15April 2021]. Available
from https://www.canada.ca/en/health-canada/services/drugs-health-products/
drug-products/applications-submissions/register-innovative-drugs.html. Acces-
sed19April2021.
50. Taubenberger, J. K. Influenzavirus hemagglutinin cleavageinto HA1, HA2: no
laughingmatter. Proc. Natl Acad. Sci. USA95,9713–9715(1998).
51. Stieneke-Gröber,A.etal.Influenzavirushemagglutininwithmultibasiccleavage
siteisactivatedbyfurin,asubtilisin-likeendoprotease.EMBOJ.11,2407–2414
(1992).PMC556715.
52. Chen,J.etal.Structureofthehemagglutininprecursorcleavagesite,adeter-
minantofinfluenzapathogenicityandtheoriginofthelabileconformation.Cell
95,409–417(1998).
53. Luczo, J. M. etal. Molecularpathogenesisof H5highlypathogenicavianinflu-
enza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,
406–430(2015).
54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical
perspective. Annu Rev. Biophys.47,153–173(2018).
55. Mc Craw, D. M., Gallagher, J. R.&Harris, A. K. Characterizationofinfluenzavaccine
hemagglutinin complexes by cryo-electron microscopy and image analyses
revealsstructuralpolymorphisms.Clin.Vaccin.Immunol.23,483–495(2016).
56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfor
insectandmammaliancells.Curr.Opin.Biotechnol.10,428–433(1999).
57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofthe
hemagglutininmoleculeof H3influenzavirusatacidicp H. Virology 126,587–599
(1983).
58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedby
broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323–341
(2015).
59. Turner, H. L. etal. Potentanti-influenza H7humanmonoclonalantibodyinduces
separation of hemagglutinin receptor-binding head domains. PLo S Biol. 17,
e3000139(2019).
60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacross
differentinfluenzavaccineplatformsinhumans.Nat.Commun.10,3338(2019).
61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus
epitope.Science324,246–251(2009).
62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizing
allinfluenza Asubtypes. Cell 166,596–608(2016).
63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in the
hemagglutininfusionmachineryoninfluenzavirions.Sci.Adv.6,eaaz8822(2020).
64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadly
neutralizingantibodiesagainststructurallydistinctdomainsof H3N2HA. Vaccines
8,99(2020).